Search

… ProQR Provides Enrollment Update on QR-110 Clinical Trial and … and retinal structure in the second half of the year. ProQR to present two abstracts on programs for Fuchs … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We look forward to the clinical data for the QR-110 …

… ProQR to Present Findings from Phase 1/2 Interim Analysis of … & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … page on the Investors section of the Company’s website, www.ProQR.com . The dial-in details for the call are +1 …

… ProQR Receives Orphan Drug Designation from FDA for QR-1123 … Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … or adRP,” said Daniel de Boer, Chief Executive Officer of ProQR. “It highlights the unmet need for patients with this …

… ProQR to Participate in a Cystic Fibrosis Panel Discussion … LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … being held at The St. Regis in New York, NY, USA.    About ProQR ProQR Therapeutics is dedicated to changing lives …

… ProQR Announces Publication in Nature Medicine of QR-110 Data … and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … is expected to start in the first half of 2019. About ProQR ProQR Therapeutics is dedicated to changing lives …

… ProQR Receives Fast Track Designation from FDA for QR-1123 … Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We look forward to beginning enrollment in the Phase …

… ProQR spins out Amylon Therapeutics as a privately-held … on central nervous system (CNS) therapeutics Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, … and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop …

… ProQR Prices Approximately $20 Million Underwritten Public … LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … $3.25 per share.  All of the shares are being offered by ProQR.  In addition, in the public offering, ProQR has …